GeNeuro S.A.
GNRO.PA
Euronext Paris0.03
EUR
- -
- -
GeNeuro S.A.
GNRO.PA
(Euronext Paris)
Recent
price
0.03
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- GeNeuro S.A. (GNRO.PA) is a clinical-stage Swiss biopharmaceutical company focused on developing treatments that neutralize pathogenic proteins from human endogenous retroviruses (HERVs) to halt the progression of neurodegenerative and autoimmune diseases, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and post-COVID neuropsychiatric syndromes; its lead product candidate is temelimab, a humanized monoclonal antibody targeting HERV-W Env (W-Env), which has completed Phase II trials in MS demonstrating impacts on key MRI markers of disease progression and is completing Phase II in long-COVID patients selected via biomarkers, with prior results presented at ECTRIMS 2022 showing potential against disability progression independent of relapses; additional candidates include GNK301, a preclinical antibody against HERV-K Env for sporadic ALS developed in partnership with the U.S. National Institute of Neurological Disorders and Stroke (NINDS/NIH), featuring new precision medicine data presented at the 2024 ALS/MND Symposium; earlier programs such as GNC-501 for post-COVID and GNbAC1 have been advanced or partnered, while Type-1 diabetes efforts are frozen to prioritize MS, ALS, and post-COVID. Founded in 2006 and headquartered in Plan-les-Ouates, near Geneva, Switzerland, with prior R&D facilities in Lyon, France, the company targets patients in these high-unmet-need areas across Europe and the U.S., leveraging HERV biology that constitutes over 8% of human DNA. In recent major changes, GeNeuro entered debt-restructuring moratorium proceedings starting September 2024 with provisional extensions through January 2025 and a definitive four-month moratorium granted May 2025, further extended to January 2026 as of September 2025 to facilitate recapitalization, asset monetization, and creditor negotiations following disappointing Phase II long-COVID results; it made all parent-company employees redundant by end-2024 with key executives continuing part-time, held an Extraordinary General Meeting in June 2025 approving board re-elections with Jesús Martin-Garcia as Executive Chairman, postponed 2024 annual and 2025 half-year financial reporting amid restructuring uncertainties, saw its French subsidiary GeNeuro Innovation SAS enter receivership in June 2025 and proceed to liquidation in July 2025 without impacting the parent's Swiss moratorium, and presented new temelimab data at ECTRIMS 2024 confirming anti-neurodegenerative effects in MS models.